title: Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.
abstract: With limited data available on the low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor (CAG) regimen in newly diagnosed older patients with acute myeloid leukemia (AML), this study aimed at comparing the efficacy and toxicity of CAG with idarubicin plus cytarabine (IA) remission induction therapy in these patients. A total of 154 consecutive patients (52 with CAG and 102 with IA) were retrospectively analyzed. The patients in the CAG group had a higher median age (68 vs. 65 years, p = 0.002) and a higher proportion of previous myelodysplastic syndrome (25.0% vs. 2.9%, p < 0.0001) compared to those in the IA group. The complete remission rates with the CAG and IA regimens were 55.8% and 52.9% (p = 0.864). The median overall survival (12.1 vs. 11.7 months, p = 0.650) and 3-year disease-free survival rates (29.6% vs. 48.6%, p = 0.657) were not statistically different in the two groups. The CAG regimen might be an alternative to conventional chemotherapy in older patients with AML.
authors.affiliation: Department of Hematology, Institute of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , China.
authors.forename: Jie
authors.initials: J
authors.lastname: Jin
authors.forename: Jian
authors.initials: J
authors.lastname: Chen
authors.forename: Shanshan
authors.initials: S
authors.lastname: Suo
authors.forename: Wenbin
authors.initials: W
authors.lastname: Qian
authors.forename: Haitao
authors.initials: H
authors.lastname: Meng
authors.forename: Wenyuan
authors.initials: W
authors.lastname: Mai
authors.forename: Hongyan
authors.initials: H
authors.lastname: Tong
authors.forename: Jian
authors.initials: J
authors.lastname: Huang
authors.forename: Wenjuan
authors.initials: W
authors.lastname: Yu
authors.forename: Juyin
authors.initials: J
authors.lastname: Wei
authors.forename: Yinjun
authors.initials: Y
authors.lastname: Lou
mesh_terms: D015250:Aclarubicin / Q000009:adverse effects / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D060828:Induction Chemotherapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D015250:Aclarubicin; D015255:Idarubicin
keywords: Acute myeloid leukemia; CAG regimen; elderly; idarubicin; priming